2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Reumatología Clínica

• Publication date

  2015-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.reuma.2015.05.001PMID 26051464
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Therapies for Active Rheumatoid Arthritis after Methotrexate Failure

  2017cited by this paper
• Costes médicos directos y sus predictores en la cohorte “Variabilidad en el manejo de la artritis reumatoide y las espondiloartritis en España”

  2016cited by this paper
• Presence of comorbidity affects both treatment strategies and outcomes in disease activity, physical function, and quality of life in patients with rheumatoid arthritis

  2015cited by this paper
• FRI0298 The Impact of DMARD Co-Therapy on Abatacept Effectiveness in Rheumatoid Arthritis Patients. A Pan-European Analysis of RA Registries

  2014cited by this paper
• Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis

  2014cited by this paper
• A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial

  2014cited by this paper
• SAT0256 Analytical and Functional Assessments When Developing Biosimilar Candidates

  2014cited by this paper
• Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis

  2014cited by this paper
• A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy.

  2014cited by this paper
• Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial

  2014cited by this paper
• Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial.

  2014cited by this paper
• Tofacitinib versus methotrexate in rheumatoid arthritis.

  2014cited by this paper
• Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration

  2014cited by this paper
• Methotrexate and Lung Disease in Rheumatoid Arthritis: A Meta‐Analysis of Randomized Controlled Trials

  2014cited by this paper
• P2. Incidence and Severity of Myocardial Infarction in Subjects Receiving Anti-Tumour Necrosis Factor Drugs for Rheumatoid Arthritis: Results from Linking the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis and Myocardial Ischaemia National Audit Project

  2014cited by this paper
• Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis

  2014cited by this paper
• Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies

  2014cited by this paper
• Dose reduction of tocilizumab in rheumatoid arthritis patients with low disease activity.

  2014cited by this paper
• Prevalence of ultrasound-detected residual synovitis and risk of relapse and structural progression in rheumatoid arthritis patients in clinical remission: a systematic review and meta-analysis.

  2014cited by this paper
• Comparative effectiveness of cycling of tumor necrosis factor-α (TNF-α) inhibitors versus switching to non-TNF biologics in rheumatoid arthritis patients with inadequate response to TNF-α inhibitor using a Bayesian approach

  2014cited by this paper
• Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial

  2014cited by this paper
• OP0026 Induction of Clinical Remission Followed by Drug-Free Withdrawal with Abatacept Combination and Monotherapy in Early RA: Results from the AVERT Study over 18 Months

  2014cited by this paper
• Sustained remission with etanercept tapering in early rheumatoid arthritis.

  2014cited by this paper
• Tofacitinib versus methotrexate in rheumatoid arthritis.

  2014cited by this paper
• Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis

  2014cited by this paper
• Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs.

  2014cited by this paper
• Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study

  2013cited by this paper
• THU0240 The Comparative Effectiveness of Oral Methotrexate Versus Subcutaneous Methotrexate for the Initial Treatment of Early Rheumatoid Arthritis

  2013cited by this paper
• A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)

  2013cited by this paper
• Predictors and persistence of new-onset clinical remission in rheumatoid arthritis patients.

  2013cited by this paper
• OP0041 Tocilizumab (TCZ) in Combination and Monotherapy Versus Methotrexate (MTX) in MTX-Naive Patients (PTS) with Early Rheumatoid Arthritis (RA): Clinical and Radiographic Outcomes from a Randomised, Placebo-Controlled Trial

  2013cited by this paper
• The Canadian Methotrexate and Etanercept Outcome Study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis

  2013cited by this paper
• Therapies for active rheumatoid arthritis after methotrexate failure.

  2013cited by this paper
• Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial

  2013cited by this paper
• Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study

  2013cited by this paper
• Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study

  2013cited by this paper
• A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study

  2013cited by this paper
• AB0501 Efficacy and safety of certolizumab pegol (CZP) with concomitant methotrexate (MTX) in korean rheumatoid arthritis (RA) patients (PTS) with an inadequate response to MTX

  2013cited by this paper
• Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.

  2013cited by this paper
• Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study

  2013cited by this paper
• Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis.

  2013cited by this paper
• Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial.

  2013cited by this paper
• Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)

  2013cited by this paper
• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

  2013influential reference
• Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial.

  2013cited by this paper
• Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial

  2013cited by this paper
• Etanercept for the treatment of rheumatoid arthritis.

  2013cited by this paper
• What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review

  2013cited by this paper
• A non-inferiority trial of an attenuated combination strategy (‘COBRA-light’) compared to the original COBRA strategy: clinical results after 26 weeks

  2013cited by this paper
• Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study

  2013cited by this paper
• Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)

  2013cited by this paper
• FATIGUE IN RHEUMATOID ARTHRITIS PATIENTS WITH LOW DISEASE ACTIVITY

  2013cited by this paper
• SAT0100 Abatacept Biologic-Free Remission Study in Established Rheumatoid Arthritis Patients orion Study

  2013cited by this paper
• Health-related quality of life and functional ability in patients with early arthritis during remission steered treatment: results of the IMPROVED study

  2013cited by this paper
• Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study

  2012cited by this paper
• Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine

  2012cited by this paper
• Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study)

  2012cited by this paper
• Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naïve patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study

  2012cited by this paper
• Low-Dose Prednisone Inclusion in a Methotrexate-Based, Tight Control Strategy for Early Rheumatoid Arthritis

  2012cited by this paper
• Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity

  2012cited by this paper
• Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study

  2012cited by this paper
• Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study

  2012cited by this paper
• Validation of ACR/EULAR definition of remission in rheumatoid arthritis from RA practice: the ESPOIR cohort

  2012cited by this paper
• Sustained rheumatoid arthritis remission is uncommon in clinical practice

  2012cited by this paper
• Rituximab or a second anti–tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti–tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register

  2012cited by this paper
• Sustained clinical remission in rheumatoid arthritis: prevalence and prognostic factors in an inception cohort of patients treated with conventional DMARDS.

  2012cited by this paper
• First in patient study of anti-GM-CSF monoclonal antibody (MOR103) in active rheumatoid arthritis: Results of a phase 1b/2a randomized, double-blind, placebo-controlled trial

  2012cited by this paper
• Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study.

  2012cited by this paper
• Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)

  2012cited by this paper
• Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial

  2012cited by this paper
• Performance of the 2011 ACR/EULAR preliminary remission criteria compared with DAS28 remission in unselected patients with rheumatoid arthritis

  2012cited by this paper
• Erratum to: Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity

  2012cited by this paper
• In patients with early rheumatoid arthritis, the new ACR/EULAR definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis

  2012cited by this paper
• Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX.

  2012cited by this paper
• A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.

  2012cited by this paper
• Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial.

  2012cited by this paper
• Validity and Reliability Problems with Patient Global as a Component of the ACR/EULAR Remission Criteria as Used in Clinical Practice

  2012cited by this paper
• Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints.

  2011cited by this paper
• Continuation of Methotrexate Resulted in Better Clinical and Radiographic Outcomes Than Discontinuation upon Starting Etanercept in Patients with Rheumatoid Arthritis: 52-week Results from the JESMR Study

  2011cited by this paper
• Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry

  2011cited by this paper
• American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.

  2011cited by this paper
• Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study

  2011cited by this paper
• Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis

  2011cited by this paper
• The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study

  2011cited by this paper
• Cancer in patients with rheumatic diseases exposed to TNF antagonists.

  2011cited by this paper
• Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis

  2011cited by this paper
• Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria

  2011cited by this paper
• Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action

  2011cited by this paper
• Aggressive therapy in patients with early arthritis results in similar outcome compared with conventional care: the STREAM randomized trial

  2011cited by this paper
• A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry

  2011cited by this paper
• The treatment of rheumatoid arthritis during pregnancy

  2011cited by this paper
• Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)

  2010cited by this paper
• Evidence for predictive validity of remission on long‐term outcome in rheumatoid arthritis: A systematic review

  2010cited by this paper
• Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

  2010cited by this paper
• Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial

  2010cited by this paper
• Rheumatoid arthritis classifi cation criteria : an American College of Rheumatology / European League Against Rheumatism collaborative initiative

  2010cited by this paper
• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

  2010cited by this paper
• Rheumatoid arthritis

  2010cited by this paper
• Remission in Early Rheumatoid Arthritis

  2010cited by this paper
• Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

  2010cited by this paper

• Survival of first line biological and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in Chile.

  2025cites this paper
• Managing Rheumatoid Arthritis in Older Adults with Cancer

  2025cites this paper
• Musculoskeletal Ultrasound Assessment Changes Management Decisions in Rheumatoid Arthritis Patients With Moderate Disease Activity

  2025cites this paper
• A clinical practice guideline for the management of the foot and ankle in rheumatoid arthritis

  2024cites this paper
• The impact of folate pathway variants on the outcome of methotrexate therapy in rheumatoid arthritis patients

  2024cites this paper
• Update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological and synthetic targeted therapies in rheumatoid arthritis.

  2024cites this paper
• Update of Modified Version of the Foot Function Index Tool Spanish Version (FFI-Sp), in Patients with Rheumatoid Arthritis: Cross Sectional Study

  2024cites this paper
• Actualización del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas y sintéticas dirigidas en la artritis reumatoide

  2024cites this paper
• La artritis reumatoide

  2023cites this paper
• Altered CD39 and CD73 Expression in Rheumatoid Arthritis: Implications for Disease Activity and Treatment Response

  2023cites this paper
• What are the core recommendations for rheumatoid arthritis care? Systematic review of clinical practice guidelines

  2023cites this paper
• Low Serum BAFF Concentration Is Associated with Response to TNF Inhibitors in Seropositive Patients with Rheumatoid Arthritis

  2022cites this paper
• Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis.

  2022cites this paper
• Increase of Circulating Monocyte–Platelet Conjugates in Rheumatoid Arthritis Responders to IL-6 Blockage

  2022cites this paper
• Remission Induced by TNF Inhibitors Plus Methotrexate is Associated With Changes in Peripheral Naïve B Cells in Patients With Rheumatoid Arthritis

  2021cites this paper
• Microfluidic-assisted electrospinning, an alternative to coaxial, as a controlled dual drug release system to treat inflammatory arthritic diseases.

  2021cites this paper
• Methotrexate Reduces the Probability of Discontinuation of TNF Inhibitors in Seropositive Patients With Rheumatoid Arthritis. A Real-World Data Analysis

  2021cites this paper
• Artritis reumatoide: Tratamiento

  2021cites this paper
• The 6-month drug survival rate in patients with rheumatoid arthritis treated with tofacitinib

  2021cites this paper
• Disease-modifying antirheumatic drug prescription patterns in adult rheumatoid arthritis patients in routine clinical practice in Spain.

  2020cites this paper
• El método Delphi en la investigación en reumatología: ¿lo estamos haciendo bien?

  2020cites this paper
• Efficacy and safety of combined therapy with synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: Systematic literature review

  2020cites this paper
• Expert recommendations on the interleukin 6 blockade in patients with rheumatoid arthritis

  2020cites this paper
• Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis.

  2020cites this paper
• Efficacy and safety of glucocorticoids in rheumatoid arthritis: Systematic literature review

  2020cites this paper
• Expert Recommendations on the Interleukin 6 Blockade in Patients with Rheumatoid Arthritis.

  2020cites this paper
• Efficacy and Safety of Combined Therapy With Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Systematic Literature Review.

  2020cites this paper
• Systematic Review of Recommendations on the Use of Disease‐Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Cancer

  2020cites this paper
• BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors

  2020cites this paper
• A Systematic Review to Identify the Effects of Biologics in the Feet of Patients with Rheumatoid Arthritis

  2020cites this paper
• Safety and survival associated with biologic therapies: first report of the Biobadaguay on the Paraguayan-Uruguayan registry of adverse events with biologic therapies

  2020cites this paper
• Efficacy and Safety of Glucocorticoids in Rheumatoid Arthritis: Systematic Literature Review.

  2020cites this paper
• Gaps between research and recommendations in rheumatoid arthritis

  2020cites this paper
• Safety and Survival Associated with Biologic Therapies: First Report of the Biobadaguay on the Paraguayan-Uruguayan Registry of Adverse Events with Biologic Therapies.

  2020cites this paper
• The Delphi method in rheumatology research: are we doing it right?

  2020cites this paper
• What Matters Most to Patients and Rheumatologists? A Discrete Choice Experiment in Rheumatoid Arthritis

  2020cites this paper
• Cost evolution of biological drugs in rheumatoid arthritis patients in a tertiary hospital: Influential factors on price.

  2019cites this paper
• Colombian Association of Rheumatology. Consensus on recommendations to decrease and discontinue biological therapy in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis

  2019cites this paper
• Treat-to-Target Strategy in Patients with Rheumatoid Arthritis: Audit of Adherence from Real World Clinical Data.

  2019cites this paper
• Asociación Colombiana de Reumatología. Consenso sobre recomendaciones para disminución y descontinuación de la terapia biológica en pacientes con artritis reumatoide, espondilitis anquilosante y artritis psoriásica

  2019cites this paper
• Evaluation of vaccination coverage in cochlear implant patients at a referral hospital in Northern Spain

  2019cites this paper
• Evaluation of vaccination coverage in cochlear implant patients at a referral hospital in Northern Spain.

  2019cites this paper
• Severity Indices in Rheumatoid Arthritis: A Systematic Review

  2019cites this paper
• Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted‐synthetic therapy for the treatment of rheumatoid arthritis

  2019cites this paper
• Methotrexate in Patients With Rheumatoid Arthritis in Spain: Subanalysis of the AR Excellence Project

  2019cites this paper
• Long-term Survival of Subcutaneous Anti-tumor Necrosis Factor Biological Drugs Administered Between 2008 and 2012 in a Cohort of Rheumatoid Arthritis Patients

  2019cites this paper
• Clinical and therapeutic management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: RADAR study

  2019cites this paper
• [An alternative therapy in a patient with rheumatoid arthritis with no possibility of treatment with methotrexate as a result of a toxic syndrome due to colza oil].

  2019cites this paper
• Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies

  2018influential citation
• Tocilizumab in the treatment of adult rheumatoid arthritis.

  2018cites this paper
• Variability in the prescription of biological drugs in rheumatoid arthritis in Spain: a multilevel analysis

  2018cites this paper
• Certolizumab pegol in a heterogeneous population of patients with moderate-to-severe rheumatoid arthritis

  2018cites this paper
• Recommendations for the use of parenteral methotrexate in rheumatic diseases.

  2018cites this paper
• New horizons for the treatment of glaucoma. I: Neuroinflammation and inflammasomes.

  2018cites this paper
• Monoterapia con fármacos biológicos en la artritis reumatoide: efecto del bloqueo de la IL-6

  2018cites this paper
• Recommendations of the Spanish Society of Rheumatology on Treatment and Use of Systemic Biological and Non-biological Therapies in Psoriatic Arthritis

  2018cites this paper
• Severity indices in rheumatoid arthritis: A systematic review.

  2017cites this paper
• Long-term survival of subcutaneous anti-tumor necrosis factor biological drugs administered between 2008 and 2012 in a cohort of rheumatoid arthritis patients.

  2017cites this paper
• Eficacia a 2 años de tocilizumab en pacientes con artritis reumatoide activa en la práctica clínica habitual

  2017cites this paper
• Recommendations by the Spanish Society of Rheumatology for the management of patients diagnosed with rheumatoid arthritis who cannot be treated with methotrexate.

  2017cites this paper
• Recomendaciones sobre el uso de metrotexato parenteral en enfermedades reumáticas.

  2017cites this paper
• Recommendations of the Spanish Society of Rheumatology on treatment and use of systemic biological and non-biological therapies in psoriatic arthritis.

  2017cites this paper
• Cirugía de la mano reumática: nuevas expectativas para una vieja conocida

  2017cites this paper
• Metotrexato en pacientes con artritis reumatoide en España: subanálisis del proyecto AR Excellence

  2017cites this paper
• Biologic Disease-modifying antirheumatic drug attributes in the first lines of treatment of rheumatoid arthritis. 2015 ACORDAR project.

  2017cites this paper
• Biomarcadores genéticos y clínicos de respuesta a Tocilizumab en pacientes con artritis reumatoide

  2017cites this paper
• Impact of genetic variants of ATP binding cassette B1, AICAR transformylase/IMP cyclohydrolase, folyl-polyglutamatesynthetase, and methylenetetrahydrofolatereductase on methotrexate toxicity.

  2017cites this paper
• Impact of Genetic Variants of ATP Binding Cassette B1, AICAR Transformylase/IMP Cyclohydrolase, Folyl-polyglutamate Synthetase, and Methylenetetrahydrofolate Reductase on Methotrexate Toxicity

  2017cites this paper
• Recommendations by the Spanish Rheumatology Society for the Management of Patients Diagnosed With Rheumatoid Arthritis who Cannot Be Treated With Methotrexate

  2017cites this paper
• Documento de Recomendaciones de la Sociedad Española de Reumatología para el manejo clínico del paciente con artritis reumatoide que no puede utilizar metotrexato

  2017cites this paper
• The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab.

  2017cites this paper
• Optimization of biological therapy in rheumatoid arthritis patients: outcomes from the CREATE registry after 2 years of follow-up

  2017cites this paper
• Two-year efficacy of tocilizumab in patients with active rheumatoid arthritis in clinical practice.

  2017cites this paper
• “Official View” on Glucocorticoids in Rheumatoid Arthritis: A Systematic Review of International Guidelines and Consensus Statements

  2017cites this paper
• Poor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: a review of data from randomized clinical trials and cohort studies

  2017cites this paper
• Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring in clinical practice: the spanish cohort of the COMORA study.

  2017cites this paper
• Impact of Genetic Variants of ATP Binding Cassette B 1 , AICAR Transformylase / IMP Cyclohydrolase , Folyl-polyglutamate Synthetase , and Methylenetetrahydrofolate Reductase on Methotrexate Toxicity

  2017cites this paper
• Impact of ultrasonography on treatment decision in rheumatoid arthritis: the IMPULSAR study

  2017cites this paper
• Methotrexate in patients with rheumatoid arthritis in Spain: Subanalysis of the AR Excellence project.

  2017cites this paper
• OFIL VOL 27-1-2017_MaquetaciÛn 1

  2017cites this paper
• Two-year efficacy of tocilizumab in patients with active rheumatoid arthritis in clinical practice.

  2017cites this paper
• Influence of patient personality in the treatment of rheumatoid arthritis

  2016cites this paper
• Cut-Offs and Response Criteria for the Hospital Universitario La Princesa Index (HUPI) and Their Comparison to Widely-Used Indices of Disease Activity in Rheumatoid Arthritis

  2016cites this paper
• [Treatment of rheumatoid arthritis].

  2016cites this paper
• [Rheumatoid arthritis at present].

  2016cites this paper
• Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study

  2016cites this paper
• Comparison of Patients with Rheumatoid Arthritis in Disease Remission in the European Union and United States

  2016cites this paper
• Documento de Recomendaciones de la Sociedad Española de Reumatología para el manejo clínico del paciente con artritis reumatoide que no puede utilizar metotrexato

  2016cites this paper
• Tratamientos biológicos en enfermedades reumatológicas y autoinmunes sistémicas

  2015cites this paper
• Efficacy and safety of glucocorticoids in rheumatoid arthritis: Systematic literature review (cid:2)

  year unknowninfluential citation
• Artritis psoriásica

  year unknowncites this paper